Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis

Peritoneal Dialysis International

Volumn 25, Issue 4, 2005, Pages 380-386

  Elwell, Rowland J ^a   Frye, Reginald F ^b   Bailie, George R ^a,c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c RENAL RESEARCH INSTITUTE   (United States)

Author keywords

Cefepime; Intraperitoneal; Peritonitis; Pharmacokinetics

Indexed keywords

CEFEPIME;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; DIALYSATE; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE;

EID: 23744497223     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500414     Document Type: Article

References (12)

1. United States Renal Data System. USRDS 2003 Annual Report: Atlas of End-Stage Renal Disease in The United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003.
2. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7:2176-82.
3. Golper TA, Brier ME, Bunke M, Schreiber MJ, Bartlett DK, Hamilton RW, et al. Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Am J Kidney Dis 1996; 28: 428-36.
4. Gahrmani N, Gorban-Brennan N, Kliger LS, Finkelstein FO. Infection rates in end-stage renal disease patients treated with CCPD and CAPD using the Ultrabag™ system. Adv Perit Dial 1995; 11:164-7.
5. Troidle L, Gorban-Brennan N, Proto F, Kliger AS, Finkelstein FO. Infectious complications among dialysis patients [Abstract]. Perit Dial Int 2000; 20(Suppl 1):S42.
6. Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, et al. International Society for Peritoneal Dialysis: Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update [Published erratum appears in Perit Dial Int 2000; 20:828-9]. Perit Dial Int 2000; 20:396-411.
7. Klasco RK. DRUGDEX® System. Greenwood Village, CO: Thomson MICROMEDEX; (edition expires September 2004).
8. Barbhaiya RH, Knupp CA, Pfeffer M, Zaccardelli D, Dukes GM, Mattern W, et al. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1992; 36:1387-91.
9. Wong KM, Chan YH, Cheung CY, Chak WL, Choi KS, Leung SH, et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis 2001; 38:127-31.
10. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing, Eleventh Informational Supplement. Wayne, PA: NCCLS;2 001:88-9.
11. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22:89-96.
12. Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19:65-70.